These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 17543155

  • 1. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis.
    Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E, Nzeusseu Toukap A, Depresseux G, Houssiau FA.
    Clin Exp Rheumatol; 2007; 25(2):287-92. PubMed ID: 17543155
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
    Fraticelli P, Fischetti C, Salaffi F, Carotti M, Mattioli M, Pomponio G, Gabrielli A.
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
    [Abstract] [Full Text] [Related]

  • 3. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
    Wanchu A, Suryanaryana BS, Sharma S, Sharma A, Bambery P.
    Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
    [Abstract] [Full Text] [Related]

  • 4. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.
    Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P.
    J Rheumatol; 2002 Nov; 29(11):2371-8. PubMed ID: 12415594
    [Abstract] [Full Text] [Related]

  • 5. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.
    Beissert S, Werfel T, Frieling U, Böhm M, Sticherling M, Stadler R, Zillikens D, Rzany B, Hunzelmann N, Meurer M, Gollnick H, Ruzicka T, Pillekamp H, Junghans V, Bonsmann G, Luger TA.
    Arch Dermatol; 2007 Dec; 143(12):1536-42. PubMed ID: 18087004
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up.
    Tochimoto A, Kawaguchi Y, Hara M, Tateishi M, Fukasawa C, Takagi K, Nishimagi E, Ota Y, Katsumata Y, Gono T, Tanaka E, Yamanaka H.
    Mod Rheumatol; 2011 Jun; 21(3):296-301. PubMed ID: 21240620
    [Abstract] [Full Text] [Related]

  • 7. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
    Naidu GSRSNK, Sharma SK, Adarsh MB, Dhir V, Sinha A, Dhooria S, Jain S.
    Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
    [Abstract] [Full Text] [Related]

  • 8. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
    Owen C, Ngian GS, Elford K, Moore O, Stevens W, Nikpour M, Rabusa C, Proudman S, Roddy J, Zochling J, Hill C, Sturgess A, Tymms K, Youssef P, Sahhar J.
    Clin Exp Rheumatol; 2016 Feb; 34 Suppl 100(5):170-176. PubMed ID: 27049330
    [Abstract] [Full Text] [Related]

  • 9. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD, Bavaliya M, Sashidharan S, Nalianda K, Sreenath S.
    Arthritis Res Ther; 2016 Jun 02; 18(1):123. PubMed ID: 27255492
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease.
    Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI.
    Clin Rheumatol; 2010 Oct 02; 29(10):1167-8. PubMed ID: 20532938
    [Abstract] [Full Text] [Related]

  • 13. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
    Goldin JG, Kim GHJ, Tseng CH, Volkmann E, Furst D, Clements P, Brown M, Roth M, Khanna D, Tashkin DP.
    Ann Am Thorac Soc; 2018 Nov 02; 15(11):1286-1295. PubMed ID: 30265153
    [Abstract] [Full Text] [Related]

  • 14. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
    Adler S, Huscher D, Siegert E, Allanore Y, Czirják L, DelGaldo F, Denton CP, Distler O, Frerix M, Matucci-Cerinic M, Mueller-Ladner U, Tarner IH, Valentini G, Walker UA, Villiger PM, Riemekasten G, EUSTAR co-workers on behalf of the DeSScipher project research group within the EUSTAR network.
    Arthritis Res Ther; 2018 Jan 30; 20(1):17. PubMed ID: 29382380
    [Abstract] [Full Text] [Related]

  • 15. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.
    Yilmaz N, Can M, Kocakaya D, Karakurt S, Yavuz S.
    Int J Rheum Dis; 2014 Nov 30; 17(8):923-8. PubMed ID: 24864029
    [Abstract] [Full Text] [Related]

  • 16. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.
    Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG.
    J Rheumatol; 2002 Feb 30; 29(2):298-304. PubMed ID: 11842824
    [Abstract] [Full Text] [Related]

  • 17. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
    Iudici M, Cuomo G, Vettori S, Bocchino M, Sanduzzi Zamparelli A, Cappabianca S, Valentini G.
    Semin Arthritis Rheum; 2015 Feb 30; 44(4):437-44. PubMed ID: 25282395
    [Abstract] [Full Text] [Related]

  • 18. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
    Ueda T, Sakagami T, Kikuchi T, Takada T.
    Respir Investig; 2018 Jan 30; 56(1):14-20. PubMed ID: 29325675
    [Abstract] [Full Text] [Related]

  • 19. Treatment Algorithms for Systemic Sclerosis According to Experts.
    Fernández-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group.
    Arthritis Rheumatol; 2018 Nov 30; 70(11):1820-1828. PubMed ID: 29781586
    [Abstract] [Full Text] [Related]

  • 20. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
    Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Sclerodema Lung Study II Investigators.
    Lancet Respir Med; 2016 Sep 30; 4(9):708-719. PubMed ID: 27469583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.